PhaseBio Pharmaceuticals Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and PhaseBio Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days PhaseBio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, PhaseBio Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 28.1 M | |
| Total Cashflows From Investing Activities | -2.7 M |
PhaseBio |
PhaseBio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in PhaseBio Pharmaceuticals on October 15, 2025 and sell it today you would earn a total of 100.00 from holding PhaseBio Pharmaceuticals or generate -100.0% return on investment over 90 days. PhaseBio Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than PhaseBio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PhaseBio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PhaseBio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PhaseBio Pharmaceuticals, and traders can use it to determine the average amount a PhaseBio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PHAS |
Based on monthly moving average PhaseBio Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PhaseBio Pharmaceuticals by adding PhaseBio Pharmaceuticals to a well-diversified portfolio.
PhaseBio Pharmaceuticals Fundamentals Growth
PhaseBio Stock prices reflect investors' perceptions of the future prospects and financial health of PhaseBio Pharmaceuticals, and PhaseBio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PhaseBio Stock performance.
| Return On Equity | -30.91 | |||
| Return On Asset | -1.06 | |||
| Operating Margin | (127.39) % | |||
| Current Valuation | 160.62 K | |||
| Shares Outstanding | 49.86 M | |||
| Price To Book | 26.18 X | |||
| Price To Sales | 4.27 X | |||
| Revenue | 10.83 K | |||
| EBITDA | 1.66 M | |||
| Cash And Equivalents | 7.8 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.36 M | |||
| Debt To Equity | 1.58 % | |||
| Book Value Per Share | (2.35) X | |||
| Cash Flow From Operations | (47.42 M) | |||
| Earnings Per Share | (2.38) X | |||
| Total Asset | 60.54 M | |||
Things to note about PhaseBio Pharmaceuticals performance evaluation
Checking the ongoing alerts about PhaseBio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PhaseBio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PhaseBio Pharmaceuticals is not yet fully synchronised with the market data | |
| PhaseBio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| PhaseBio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| PhaseBio Pharmaceuticals currently holds 1.36 M in liabilities with Debt to Equity (D/E) ratio of 1.58, which is about average as compared to similar companies. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 10.83 K. Net Loss for the year was (131.07 K) with loss before overhead, payroll, taxes, and interest of (91.28 M). | |
| PhaseBio Pharmaceuticals currently holds about 7.8 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 55.0% of PhaseBio Pharmaceuticals shares are owned by institutional investors |
- Analyzing PhaseBio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PhaseBio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining PhaseBio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PhaseBio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PhaseBio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PhaseBio Pharmaceuticals' stock. These opinions can provide insight into PhaseBio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in PhaseBio Stock
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |